EPOC

European Paediatric Oncology Off-Patent Medicines Consortium

 Coordinatore UNIVERSITY OF NEWCASTLE UPON TYNE 

 Organization address address: Kensington Terrace 6
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU

contact info
Titolo: Ms.
Nome: Nicola
Cognome: Place
Email: send email
Telefono: +44 191 222 5130
Fax: +44 191 222 5920

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 2˙575˙594 €
 EC contributo 1˙997˙862 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-B
 Funding Scheme CP-FP
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-02-01   -   2013-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY OF NEWCASTLE UPON TYNE

 Organization address address: Kensington Terrace 6
city: NEWCASTLE UPON TYNE
postcode: NE1 7RU

contact info
Titolo: Ms.
Nome: Nicola
Cognome: Place
Email: send email
Telefono: +44 191 222 5130
Fax: +44 191 222 5920

UK (NEWCASTLE UPON TYNE) coordinator 379˙683.86
2    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

 Organization address address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149

contact info
Titolo: Dr.
Nome: Carola
Cognome: Brieger
Email: send email
Telefono: +49 251 83 24749
Fax: +49 251 83 21501

DE (MUENSTER) participant 900˙467.00
3    ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

 Organization address address: Via Giuseppe La Masa 19
city: MILANO
postcode: 20156

contact info
Titolo: Dr.
Nome: Maurizio
Cognome: D'incalci
Email: send email
Telefono: +39 02 39014473
Fax: +39 0239014734

IT (MILANO) participant 194˙541.14
4    UNIVERSITE D'AIX MARSEILLE

 Organization address address: Boulevard Charles Livon 58
city: Marseille
postcode: 13284

contact info
Titolo: Ms.
Nome: Celine
Cognome: Damon
Email: send email
Telefono: +33 491 998595

FR (Marseille) participant 188˙572.00
5    POWERTRIAL LIMITED

 Organization address address: MARQUIS COURT UNIT A2 TEAM
city: NEWCASTLE
postcode: NE11 0RU

contact info
Titolo: Ms.
Nome: Rachael
Cognome: Hogg
Email: send email
Telefono: +44 191 4973363
Fax: +44 870 4215295

UK (NEWCASTLE) participant 84˙200.00
6    CANCER RESEARCH UK

 Organization address address: ST JOHN STREET 407 ANGEL BUILDING
city: LONDON
postcode: EC1V 4AD

contact info
Titolo: Ms.
Nome: Robina
Cognome: Ibanda
Email: send email
Telefono: +44 207 438 5366
Fax: +44 207 438 5451

UK (LONDON) participant 75˙750.00
7    AZIENDA OSPEDALIERA DI PADOVA

 Organization address address: Via Giustiniani 1
city: PADOVA
postcode: 35128

contact info
Titolo: Dr.
Nome: Antonio
Cognome: Giona
Email: send email
Telefono: +39 049 8211590
Fax: +39 049 8211593

IT (PADOVA) participant 71˙649.00
8    UNIVERSITY COLLEGE LONDON

 Organization address address: GOWER STREET
city: LONDON
postcode: WC1E 6BT

contact info
Titolo: Ms.
Nome: Greta
Cognome: Borg-Carbott
Email: send email
Telefono: +44 20 3108 3033
Fax: +44 20 7813 2849

UK (LONDON) participant 52˙999.00
9    CONFEDERACION INTERNACIONAL DE ORGANIZACIONES DE PADRES DE NINOS CON CANCER ASOCIACION

 Organization address address: PLAZA PABLO PICASSO 9 3 D
city: VALENCIA
postcode: 46015

contact info
Titolo: Dr.
Nome: Marianne
Cognome: Naafs-Wilstra
Email: send email
Telefono: +31 30 2422944
Fax: +31 30 2422945

ES (VALENCIA) participant 50˙000.00
10    INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL

 Organization address address: Old Brompton Road 123
city: LONDON
postcode: SW7 3RP

contact info
Titolo: Mr.
Nome: Yodry
Cognome: Vasquez
Email: send email
Telefono: +44 207 153 5296
Fax: +44 207 370 5261

UK (LONDON) participant 0.00
11    UNIVERSITY OF LEICESTER

 Organization address address: University Road
city: LEICESTER
postcode: LE1 7RH

contact info
Titolo: Ms.
Nome: Marie
Cognome: Singer
Email: send email
Telefono: +44 116 223 1799
Fax: +44 116 252 2028

UK (LEICESTER) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

childhood    oncology    epoc    doxorubicin    treatment    successful    done    national    pharmacologists    children    list    regulatory    drugs    emea    meet    cancers    drug    data    determine    cancer    paediatric    group    wider    groups    pharmacokinetics    patients    child    oncologists    dose    toxicities   

 Obiettivo del progetto (Objective)

'Cancer chemotherapy has a key role in the successful treatment of a number of childhood cancers. Nevertheless, at least 20% of patients are not cured by current therapies and a significant number experience debilitating toxicities. Given the high cure rates and potential life-span of survivors of childhood cancer, it is particularly important to minimize the impact of potential chronic toxicities. For several of the most widely-used drugs, little is known about their pharmacokinetics and metabolism in children, particularly very young children (<3 years). There are many examples where such knowledge has been used to optimize the use of chemotherapeutic drugs, both to avoid toxicity and to maximize the therapeutic effect. The need for further research to investigate these drugs in children is acknowledged in the Priority List for Studies into Paediatric Medicinal Products, issued by the EMEA. Doxorubicin is on this list and is one of the most important drugs used in the treatment of childhood cancers. Several national groups have been successful in studying the pharmacology of drugs used in paediatric oncology. However, in order to recruit sufficient patient numbers for meaningful studies it is necessary to establish a wider group, bringing together the successful elements of established national organizations. The EPOC group combines leading pharmacologists, paediatric oncologists, regulatory organizations and a management structure which will successfully deliver data of appropriate quality on which to base future clinical use of this drug and to meet the demands of the EMEA priority list. Such data will form the basis of future applications for Paediatric Usage Marketing Authorization for doxorubicin. The overall aim of the consortium is to provide data that will guide the optimal use of this drug in the clinic, and also meet the regulatory requirements of the EMA.'

Descrizione progetto (Article)

Research has been done before to determine the pharmacological action of drugs used in paediatric oncology. However, a wider, larger group of child patients is needed to really get enough information.

An EU-funded project, ?European paediatric oncology off-patent medicines consortium? (EPOC), is addressing the issue with the help of leading pharmacologists, paediatric oncologists and regulatory organisations.

Doctors usually determine dosage based on studies done in adult patients. They lower the dose for safety, but often toxic effects will persist or the dose will be too low to destroy the tumour. In other words, a narrow window of effective therapy exists, which must be determined by characterising how the drug is absorbed and metabolised in children. This is known as the pharmacokinetics of the drug.

By taking various child age groups into account, the research is set to greatly improve the treatment of paediatric cancer.

Altri progetti dello stesso programma (FP7-HEALTH)

FAST-XDR-DETECT (2008)

Development of a two-approach plate system for the fast and simultaneous detection of MDR and XDR M. tuberculosis

Read More  

CLOSED (2013)

Clonidine for Sedation of Paediatric Patients in the Intensive Care Unit

Read More  

I-DCC (2009)

“The International Data Coordination Centre”

Read More